Company Profile
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Theraflu, and Flonase brands for respiratory issues; and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. Haleon plc has a collaboration agreement with Microsoft to scale digital, data and AI capabilities across the business and accelerate delivery of its global win as one strategy. Haleon plc was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. The company was founded in 1715 and is headquartered in Weybridge, the United Kingdom.
Latest News
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Website | https://www.haleon.com |
| Audit Risk | 3 |
| Board Risk | 1 |
| Overall Risk | 1 |
| Market Cap | 32.30B |
| Trailing P/E | 19.3 |
| Forward P/E | 16.18 |
| Dividend Rate | 0.07 |
| Dividend Yield | 1.96% |
| Trailing Annual Div. Rate | 0.07 |
| Trailing Annual Div. Yield | 0.02% |
| Trailing EPS | 0.19 |
| Forward EPS | 0.23 |
| Book Value | 1.84 |
| Price-to-Book | 198.86 |
| Enterprise-to-Revenue | 3.6 |
| Enterprise-to-EBITDA | 14.48 |
| Ex-Dividend Date | 04/09/2026 |
| Earnings Date | 07/30/2026 |
| Earnings Call Date | 07/30/2026 |
| Revenue Average | 2.87B |
| Revenue Low | 2.87B |
| Revenue High | 2.87B |